Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogenerics Bill From Pallone/Deal Is A Mere 98 Questions Away From Consensus

Executive Summary

House Energy & Commerce Health Subcommittee staffers will need an extra-large spread sheet to find the consensus in stakeholder positions on follow-on biologics legislation

You may also be interested in...

Frank Torti’s Next 100 Days: Active, Not Just Acting FDA Commissioner

Frank Torti might not be in charge of FDA for very long, but he seems determined to make his time count

Torti's Next Hundred Days: Active, Not Just Acting FDA Commissoner

FDA's Chief Scientist will continue to push for outside academic collaborations during his "short time" atop the agency; fall letter on follow-on biologics could draw closer reading.

Most Biosimilars Would Need Clinical Trials, ASCO Tells House Panel

While urging Congress to write legislation that allows FDA to decide which scientific data are needed to approve follow-on biologics, comments from the American Society of Clinical Oncology to a House subcommittee note that clinical trials will be necessary for most FOBs

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts